Clinical & Experimental Cardiology
Open Access
ISSN: 2155-9880
+44 1300 500008
ISSN: 2155-9880
+44 1300 500008
Mebratu Alebachew Gebrie
University of Verona, Italy
Posters & Accepted Abstracts: J Clin Exp Cardiolog
Background: King et al., first time described percutaneous trans-catheter closure in 1976. After that, with time after Pediatric population, catheter interventions for atrial septal defect (ASD) have been adapted for adult population. The most useful clinical benefits of this procedure are the significant improvement of symptoms and routine life activities without major cardiac surgery. Objectives: This study aimed to assess a single institutional experience of the ASD closure and patent foramen ovale repair early and late outcome after percutaneous transcatheter closure. Methods: A retrospective observational cohort study designed for percutaneous PFO/ASD closure patients at a single center. We enrolled study group from February 2000 to June 2015. We collected data from patientâ��s electronic folders. In entire population, N=126 (80%) and N=25 (20%) of the patients underwent PFO and ASD closure, respectively. Results: Our total population consisted of with 149 patients mean age 50.5�±11 years underwent percutaneous PFO and ASD closure. The mean device size was 19.3�±6.2 mm for ASD patients and 24.6�±2.6 mm for PFO patients. The mean procedural and fluoroscopy times were 21.2�±3.5 and 3.8�±2.2 minutes for ASD closure and 12.4�±3.2 and 3.1�±1.2 minutes for PFO closure, respectively. Device deployment rate was 100% successful. Transesophageal echocardiogram was used in 65% of patients during device implantation. Post-procedural, 92% of patients were discharged home without any complications. N=2 (1.3%), N=1 (0.7%), and N=1 (0.7%) patients observed with atrial fibrillation, infection and allergic reaction, respectively. Conclusion: Trans-catheter percutaneous PFO and ASD can be done in adults safely with relatively less procedural and postprocedural complications.
Email: mebanat@yahoo.com